
KaliVir Immunotherapeutics, Inc.
- KaliVir Immunotherapeutics, Inc. just raised $14M (Series A Extension) on Aug 19
Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.
About
KaliVir Immunotherapeutics is a clinical-stage biotechnology company focused on developing innovative, multi-mechanistic oncolytic immunotherapy programs. The company leverages its proprietary Vaccinia Enhanced Template (VET™) platform to engineer vaccinia viruses that selectively replicate in and kill cancer cells, while also stimulating anti-tumor immunity and modifying the tumor microenvironment. Their product candidates are designed for systemic intravenous delivery to treat various cancer types.
Show 6 more similar companies
Similar companies
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.
Shares Biotechnology, Drug Discovery
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Biotech
A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.
Shares Biotechnology, Life Sciences
Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.
Shares Biotechnology, Pharmaceuticals
Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.
Shares Biotechnology, Biotech
Signals agent
Reach companies that have budget right now
Every week the agent finds companies in your market that just got money or started hiring to spend it, and the person to talk to. You choose who to reach; nothing is sent for you.
- Just raised a roundFresh budget, the week it lands
- Hiring sales and marketingGo-to-market roles mean money to spend
- Hiring fastA jump in open roles across the company
- In the newsLaunches and announcements worth a message
- The decision makerWho to contact, with a message you can edit
Is your startup an alternative to KaliVir Immunotherapeutics, Inc.?
People comparing tools land here. Get listed beside these.
Copy KaliVir Immunotherapeutics, Inc.'s SEO strategy
How often they publish, which searches their posts chase and their newest posts. Then outrank them.
All funding rounds
Key facts
- Website
- kalivir.com
- Headquarters
- Pittsburgh, United States
- Founded
- 2019
- Employees
- 29
- Total funding
- $14M (Series A Extension)
- Business model
- B2B
Funding rounds
- $14M19 Aug 2026
Led by Company K Partners
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 19 Aug 2026 | Series A Extension | $14M | Company K Partners |
Tech stack
Detected on kalivir.com, last scanned 4 Nov 2026. Run your own scan
- Frontend
- jQuery
- SEO
- All in One SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Microsoft 365
Benchmarking
See how your site ranks against 16,849 startups
KaliVir Immunotherapeutics, Inc. sits in the 17th percentile for Domain Rating. Check where yours lands, free.
KaliVir Immunotherapeutics, Inc. has a Domain Rating of 10, the 17th percentile of 16,849 startups we track.
Measured, not editorial
Ahrefs DR
Bottom 25%
Check yoursEffective DR
Bottom 25%
Check yoursAgent Readiness
Above median
Scan yoursSite Speed
Below median
PageSpeedData Trust
Above median
Security
Click to scan
Agent Readiness
Can AI agents use your site?
KaliVir Immunotherapeutics, Inc. scores 45. Check yours free in a few seconds, or let Max Agent rerun it daily.
Run it daily with Max AgentGet notified when KaliVir Immunotherapeutics, Inc. changes
Used KaliVir Immunotherapeutics, Inc.? Write a review and get $5 in credits
Your first review on StartupHub.ai adds 1,250 credits to your account. Spend them on:
- Email finder
- Market Map Maker
- Agent Readiness scans
- Deep intel
- Tech stack scans
Frequently asked
Is KaliVir Immunotherapeutics, Inc. growing?
Yes, fast. Our data shows it raised $14M in a Series A Extension in August 2026.
Who owns KaliVir Immunotherapeutics, Inc.?
KaliVir Immunotherapeutics, Inc. is privately held, owned by its founders and investors. Investors on record include Company K Partners, SV Investment, Flexus Partners and Nextrans. Exact stakes are not public.
Are there companies like KaliVir Immunotherapeutics, Inc.?
Yes. We list 6 companies like KaliVir Immunotherapeutics, Inc., including Moderna, BioNTech and Epicrispr Biotechnologies.
What is KaliVir Immunotherapeutics, Inc.'s Effective Domain Rating?
StartupHub's Effective Domain Rating for KaliVir Immunotherapeutics, Inc. is 9 out of 100, measuring real cross-surface visibility in search engines and AI answers rather than claimed link authority. That is fairly rated against its Ahrefs Domain Rating of 10.
Is KaliVir Immunotherapeutics, Inc. trustworthy and reputable?
StartupHub's Data Trust & Reputation score for KaliVir Immunotherapeutics, Inc. is 76 out of 100, a generally safe rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has KaliVir Immunotherapeutics, Inc. raised?
KaliVir Immunotherapeutics, Inc. has raised a total of $14M in funding. The most recent round on record is Series A Extension.
How many employees does KaliVir Immunotherapeutics, Inc. have?
KaliVir Immunotherapeutics, Inc. has approximately 29 people on record.
SEC filings, insider activity, nonprofit links and pay benchmarks for KaliVir Immunotherapeutics, Inc.:
Company details: from public sources. Funding: 1 round on file. Ownership: not yet claimed by the company. Scores: measured by named tools; each links to its method. Our rules
Categories
Max Agent
Let Max Agent watch KaliVir Immunotherapeutics, Inc. and its market for you
New competitors, funding rounds, pricing and product changes, and where you show up in AI answers, in one weekly report.
Free week
Starter listings, once
AI answers checked
Daily for 7 days
ChatGPT
Perplexity
Max Agent
$79 a month, or $9.99 with our badge on your site
AI answers checked
Every week
ChatGPT
Claude
Perplexity
Gemini

